Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review

Miguel Ruiz,Alexandra Cocores,Antonella Tosti,Peter J Goadsby,Teshamae S Monteith

DOI: https://doi.org/10.1177/03331024221143538

2023-02-07

Cephalalgia

Abstract:Cephalalgia, Volume 43, Issue 2, February 2023. BackgroundAlopecia is associated with erenumab post-marketing, but no cases have been described.MethodsWe describe two patients that reported temporary hair loss and review the FDA Adverse Event Reporting System (FAERS).ResultsThe first patient experienced alopecia within three months of starting erenumab, which did not improve with ongoing use or transition to fremanezumab. The second patient reported alopecia within two weeks of starting erenumab, which continued after transition to galcanezumab; months later, there was also recurrent hair loss within one month of starting fremanzeumab. According to FAERS (last accessed 18 August 2022), alopecia was reported most with erenumab (1158), followed by galcanezumab (554), fremanezumab (175), eptinezumab (23), rimegepant (26), ubrogepant (4), and atogepant (3).ConclusionMost events were reported in women and non-serious. The potential mechanism of alopecia with drugs targeting calcitonin gene-related peptide or its receptor possibly includes disruptions in the microvascular circulation and other homeostatic mechanisms.

neurosciences,clinical neurology